Ear5 Inhibitors
Ear5 inhibitors are a class of chemical compounds characterized by their ability to specifically interact with the Ear5 protein, modulating its activity within cellular systems. These inhibitors generally exhibit structural motifs that allow them to bind to the Ear5 protein's active or allosteric sites, disrupting its normal function and affecting downstream biochemical pathways. The specificity of Ear5 inhibitors lies in their capacity to recognize and interact with key domains of the protein, often through hydrogen bonding, hydrophobic interactions, or van der Waals forces, contributing to high binding affinity and selectivity. The design of Ear5 inhibitors often leverages insights from structural biology and molecular modeling, enabling the identification of small molecules that fit the unique conformational landscape of the Ear5 protein's binding site. This binding can lead to competitive or non-competitive inhibition, depending on whether the inhibitor interacts directly with the active site or induces a conformational change in the protein to prevent substrate binding.
Chemically, Ear5 inhibitors vary in their core structures but often include aromatic rings, heterocycles, and functional groups like hydroxyls, amides, or halogens, which enhance binding interactions and improve solubility. These compounds may be optimized for different physicochemical properties, such as increased bioavailability or metabolic stability, although their primary design goal is potent inhibition of the Ear5 protein's function. Through various derivatization processes, analogs of known Ear5 inhibitors are synthesized and tested to enhance activity, improve specificity, and modulate pharmacokinetic properties. Structural-activity relationship (SAR) studies play a critical role in understanding how different substituents on the core scaffold impact the inhibitory activity. Overall, the development of Ear5 inhibitors encompasses both structure-based and ligand-based approaches, focusing on creating molecules that can effectively disrupt Ear5's role in its respective biochemical pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
Inhibits Rnase2b by targeting neutral sphingomyelinase (nSMase), disrupting sphingomyelin metabolism. This disrupts extracellular vesicle release and influences chemotaxis and mucosal immune responses by altering the composition of the extracellular space. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Acts as an indirect inhibitor by targeting p38 MAPK, modulating chemotaxis pathways associated with Rnase2b. This influences the gene's participation in chemotactic responses by affecting downstream signaling events in innate immune responses in mucosa. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Acts as an indirect inhibitor by targeting PI3K, modulating chemotaxis pathways associated with Rnase2b, and altering its participation in chemotactic responses. This impacts downstream signaling events and cellular processes related to mucosal immune responses. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
Inhibits c-Jun N-terminal kinase (JNK), impacting innate immune responses in mucosa and indirectly suppressing Rnase2b through immune-related signaling pathways. This influences the gene's participation in chemotactic responses by affecting downstream JNK-mediated events. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Disrupts lysosomal acidification, affecting the subcellular localization of Rnase2b and impairing its function due to mislocalization within the cell. This alters the gene's participation in ribonuclease activity and chemotactic responses associated with the extracellular space. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits Rnase2b indirectly by targeting PI3K, modulating chemotaxis pathways, and influencing its participation in chemotactic responses. This impacts downstream signaling events and cellular processes related to mucosal immune responses, altering the gene's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Targets MEK1/2 within the MAPK/ERK pathway, indirectly inhibiting Rnase2b. This influences downstream cellular responses associated with ribonuclease activity and chemotaxis, altering the gene's participation in extracellular space and mucosal immune responses. | ||||||
JNK Inhibitor XVI | 1410880-22-6 | sc-364745 | 10 mg | $350.00 | 5 | |
Inhibits JNK, impacting innate immune responses in mucosa and suppressing Rnase2b through immune-related signaling pathways. This influences the gene's participation in chemotactic responses by affecting downstream JNK-mediated events and cellular processes. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Affects lysosomal acidification, disrupting the subcellular localization of Rnase2b and impairing its function. This alteration in localization influences the gene's participation in ribonuclease activity and chemotactic responses associated with the extracellular space. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
Targets Src kinase, modulating chemotaxis pathways associated with Rnase2b, influencing its participation in chemotactic responses. This impacts downstream signaling events and cellular processes related to mucosal immune responses, altering the gene's function. | ||||||